The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent BTK inhibitors with fewer adverse events in mantle cell lymphoma.
Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non–Small Cell Lung Cancer in Brazil Among 273 patients, cCRT and sCRT were administered with equal ...
Objective Postmarketing safety data of avacopan, the first Food and Drug Administration (FDA) approved drug in a decade for ...
Erratum: Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance Retrospective, ...
In the past, the software was a monolith that was built. There is a single gigantic entity of code that is all tightly ...
Testing to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and factors ...
Pharma and biotech companies have access to an unprecedented variety of health data, from electronic health records and medical or pharmacy claims to genomic, behavioral and sensor data. Yet it can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results